Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Nondisplaceable Binding Is a Potential Confounding Factor in C-11-PBR28 Translocator Protein PET Studies

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Structural brain abnormalities associated with cognitive impairments in bipolar disorder

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. NeuroPharm study: EEG wakefulness regulation as a biomarker in MDD

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Parkinson patients have a presynaptic serotonergic deficit: A dynamic deep brain stimulation PET study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Karolinska Schizophrenia Project Consortium
Vis graf over relationer

The PET ligand 11C-PBR28 (N-((2-(methoxy-11C)-phenyl)methyl)-N-(6-phenoxy-3-pyridinyl)acetamide) binds to the 18-kDa translocator protein (TSPO), a biomarker of glia. In clinical studies of TSPO, the ligand total distribution volume, VT, is frequently the reported outcome measure. Since VT is the sum of the ligand-specific distribution volume (VS) and the nondisplaceable-binding distribution volume (VND), differences in VND across subjects and groups will have an impact on VTMethods: Here, we used a recently developed method for simultaneous estimation of VND (SIME) to disentangle contributions from VND and VS Data from 4 previously published 11C-PBR28 PET studies were included: before and after a lipopolysaccharide challenge (8 subjects), in alcohol use disorder (14 patients, 15 controls), in first-episode psychosis (16 patients, 16 controls), and in Parkinson disease (16 patients, 16 controls). In each dataset, regional VT estimates were obtained with a standard 2-tissue-compartment model, and brain-wide VND was estimated with SIME. VS was then calculated as VT - VND VND and VS were then compared across groups, within each dataset. Results: A lower VND was found for individuals with alcohol-use disorder (34%, P = 0.00084) and Parkinson disease (34%, P = 0.0032) than in their corresponding controls. We found no difference in VND between first-episode psychosis patients and their controls, and the administration of lipopolysaccharide did not change VNDConclusion: Our findings suggest that in TSPO PET studies, nondisplaceable binding can differ between patient groups and conditions and should therefore be considered.

TidsskriftJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Udgave nummer3
Sider (fra-til)412-417
Antal sider6
StatusUdgivet - mar. 2021

ID: 65897030